These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 9407433)
1. Progression of renal failure: role of apolipoprotein B-containing lipoproteins. Attman PO; Samuelsson O; Alaupovic P Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433 [TBL] [Abstract][Full Text] [Related]
2. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Attman PO; Alaupovic P; Tavella M; Knight-Gibson C Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654 [TBL] [Abstract][Full Text] [Related]
3. Cholesterol metabolism in glomerular cells: effect of lipoproteins from nephrotic patients. Wanner C; Krämer-Guth A; Nauck M; Quaschning T; Pavenstädt H; Schollmeyer P Miner Electrolyte Metab; 1996; 22(1-3):39-46. PubMed ID: 8676822 [TBL] [Abstract][Full Text] [Related]
4. Increased concentrations of Apo B-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure. Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P Miner Electrolyte Metab; 1992; 18(2-5):199-202. PubMed ID: 1465058 [TBL] [Abstract][Full Text] [Related]
5. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799 [TBL] [Abstract][Full Text] [Related]
6. The compositional abnormalities of lipoproteins in diabetic renal failure. Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P Nephrol Dial Transplant; 1998 Nov; 13(11):2833-41. PubMed ID: 9829487 [TBL] [Abstract][Full Text] [Related]
8. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484 [TBL] [Abstract][Full Text] [Related]
9. The effect of decreasing renal function on lipoprotein profiles. Attman PO; Samuelsson O; Alaupovic P Nephrol Dial Transplant; 2011 Aug; 26(8):2572-5. PubMed ID: 21220758 [TBL] [Abstract][Full Text] [Related]
10. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P Nephron; 1997; 75(3):286-94. PubMed ID: 9069450 [TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men. Chan DC; Watts GF; Ng TW; Uchida Y; Sakai N; Yamashita S; Barrett PH Clin Biochem; 2005 Sep; 38(9):806-12. PubMed ID: 15992790 [TBL] [Abstract][Full Text] [Related]
12. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160 [TBL] [Abstract][Full Text] [Related]
13. [Anomalies of lipoprotein metabolism in chronic renal insufficiency]. Lacour B; Massy ZA; Jungers P; Drueke T Nephrologie; 1993; 14(2):75-90. PubMed ID: 8327031 [TBL] [Abstract][Full Text] [Related]
14. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474 [TBL] [Abstract][Full Text] [Related]
15. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Tremblay AJ; Lamarche B; Cohn JS; Hogue JC; Couture P Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1101-6. PubMed ID: 16528005 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein metabolism and renal failure. Attman PO; Samuelsson O; Alaupovic P Am J Kidney Dis; 1993 Jun; 21(6):573-92. PubMed ID: 8503411 [TBL] [Abstract][Full Text] [Related]
17. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467 [TBL] [Abstract][Full Text] [Related]
18. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis]. Kes P; Reiner Z; Brunetta B Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979 [TBL] [Abstract][Full Text] [Related]
19. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090 [TBL] [Abstract][Full Text] [Related]
20. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. Samuelsson O; Attman PO; Knight-Gibson C; Larsson R; Mulec H; Weiss L; Alaupovic P J Am Soc Nephrol; 1998 Aug; 9(8):1482-8. PubMed ID: 9697671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]